Apyx Keeps $60 Million 2026 Target as AYON Adds Power Lipo-Can the New Indication Keep the Run-Rate Rising?

Apyx held its 2026 target, but the quarter still needs stronger follow-through

Apyx posted a solid second quarter, yet not one that fully silences skepticism. It reported $13.9 million Q2 revenue, and Surgical Aesthetics remained the main driver at $12.4 million in segment revenue. More importantly, management still backs $59.0 million to $60.0 million of FY2026 revenue with only half the year complete. That is a confident number to hold, but it still leaves the market looking for proof that the second half can carry the year.

Why the guidance matters

The key question is not whether the quarter was decent. It is whether management sees enough demand momentum to support the full-year target without a reset. If confidence had weakened, trimming guidance early would have been the obvious move. Instead, Apyx kept the target intact while also advancing a catalyst: a limited commercial launch of the power liposuction handpiece rather than a full rollout.

That keeps the setup promising but not risk-free. If the second half needs to run faster, investors need evidence that AYON can do more than support the base business.

FDA-cleared power liposuction gives AYON a clearer use case

Power liposuction matters because it expands what AYON can do in one platform, not just adds another checkbox. If surgeons can use that capability regularly, the company has a better case for repeat purchases and higher consumable use.

Two liposuction modes on one cart

FDA clearance now covers power liposuction as a second advanced liposuction modality on AYON. Apyx says the feature is expected to reduce a surgeon's effort and operating room time, which gives the platform a practical workflow advantage. In practice, that means surgeons can perform both standard fat removal and power-assisted fat removal on the same system, potentially simplifying the OR setup.

Apyx is also positioning AYON to address demand for skin laxity and body contouring procedures linked to the GLP-1 weight-loss trend. That does not prove demand will arrive, but it does broaden the pitch: a system that combines fat removal with tissue contraction may appeal to surgeons treating patients with loose skin after weight loss.

Why the expansion matters economically

The upside is not just a wider label. It is the possibility that the platform becomes more embedded in daily practice:

• Broader appeal: some surgeons may buy AYON for fat removal, others for tightening, and some for both.
• Stronger workflow fit: once training and instrument setup center on one system, replacing it becomes less straightforward.
• More consumable pull-through: if AYON does more during a case, the installed base can generate more single-use handpiece demand over time.

That is the real upside: not simply a new indication, but more frequent use and more consumable intensity per case.

Initial shipments are underway, but utilization is still the proof point

This is no longer just a regulatory headline. Apyx completed initial commercial shipments in June 2026 as part of a limited commercial launch to key surgeons in critical geographies. The company has also said the rollout is meant to refine training, utilization, and the overall customer experience before scaling. That is a measured approach, but it also means the market still needs evidence that the feature can drive real adoption.

The quarter did show a healthier core backdrop: gross profit margin improved to 63.9% from 62.3%, helped by a mix shift toward surgical aesthetics. If power liposuction raises consumable use, margin expansion could follow later. For now, though, the near-term task is proving that the new mode changes surgeon behavior rather than just widening the feature set.

What investors should watch over the next two quarters

Over the next two quarters, the story shifts from whether Apyx can defend its target to whether the business is improving in quality. Management still sees enough demand to support $59.0 million to $60.0 million of FY2026 revenue even while running a limited launch. If investors begin to view AYON as an expanding platform, the stock could respond before the annual numbers are fully proven.

Watch the revenue mix

The clearest near-term signal is OEM. In Q2, OEM revenue was about $1.5 million, down 12% from a year earlier. That softness fits Apyx's broader shift toward surgical aesthetics, but investors still need to see whether Surgical Aesthetics can continue absorbing the weight of the business.

Watch for: - Surgical Aesthetics to keep driving growth while OEM remains soft. - Evidence from the limited commercial launch that demand is spreading beyond a small group of early adopters.

Watch the margin trade-off

Management expects gross margins to face pressure in the second half as the new power liposuction handpieces ramp. That is not automatically bearish. If the new handpiece increases usage, deepens platform reliance, and drives more consumable pull-through, near-term margin pressure can give way to a better mix later.

Watch for: - Apyx using the ramp period to refine training, utilization, and the overall customer experience before scaling. - No fresh weakness in the broader aesthetic demand engine while the company absorbs early manufacturing costs for the new handpieces.

If those signals improve together, Apyx will have a stronger case that AYON's label expansion is becoming a real growth driver.